Rare Disease Intelligence.Global ClinicalAccess.
Pharma²⁸ is a rare disease intelligence and market access platform based in Kendall Square, Cambridge, at the center of the Boston biotech ecosystem. We connect U.S. biotech innovation with clinical, regulatory, data and patient-access opportunities in Brazil and other international markets, supporting the responsible development of therapies for rare and ultra-rare diseases.
At the intersection of biotech innovation, clinical development, market access and rare disease intelligence.
Pharma²⁸ works at the intersection of biotech innovation, clinical development, market access and rare disease intelligence.
By combining medical expertise, market intelligence, strategic partnerships and AI-enabled data infrastructure, Pharma²⁸ helps biotech companies identify where international expansion, clinical validation, real-world evidence and local access strategies can create value for patients and for innovation-driven companies.
The gap between scientific promise and patient access.
Promising therapies often face delays not because the science lacks potential, but because the path from innovation to patient is fragmented.
Biotech companies may need the right investigators, patient cohorts, clinical centers, regulatory pathways, data strategy, local partnerships and market-access intelligence before a therapy can move meaningfully toward patients in international markets.
An integrated model for international rare disease development.
Pharma²⁸ works at the intersection of rare diseases, clinical development, market access, data intelligence and international strategy.
Our platform combines medical and scientific expertise with AI-enabled data infrastructure to help biotech companies evaluate where international expansion can create clinical, strategic and patient-access value.
Six areas of work, coordinated as one pathway.
Rare Disease Opportunity Assessment
Evaluate whether Brazil or other international markets may be relevant for a specific rare disease therapy or clinical program.
Clinical and Medical Feasibility
Identify centers of excellence, map specialist networks and connect biotech companies with experienced medical leaders.
Brazil Market Entry and Activation
Understand and activate the Brazilian opportunity through clinical, regulatory, institutional, data and patient-access strategy.
Patient Identification and Diagnostic Intelligence
Combine medical expertise, curated evidence and AI-enabled infrastructure to find where relevant patients may be concentrated.
Regulatory Pathway Support
Evaluate pathways for clinical studies, early access, compassionate use, evidence generation and long-term registration.
Real-World Evidence and Data Generation
Explore how clinical datasets, physician insight and local experience can support development decisions.
From strategic alignment to a practical path forward.
- 01Align
Assess the therapy, disease area, target population, clinical context, market opportunity, regulatory considerations, data landscape and local stakeholder ecosystem.
- 02Map
Disease and market opportunity assessment, clinical expert mapping, patient cohort and diagnostic pathway analysis.
- 03Structure
Regulatory and access pathway review, institutional and academic engagement, real-world evidence planning.
- 04Activate
Early access or clinical collaboration strategy, local partnership development, strategic execution support.
- 05Sustain
Build long-term pathways for adoption, evidence generation and responsible patient access.
One of the world's most important and underused engines for clinical innovation.
With a single-market population of more than 200 million people, Brazil offers scale, clinical depth, experienced investigators, advanced academic hospitals, large public-health programs and patient cohorts that are often difficult to identify or access through traditional development pathways.
At the center of the Boston biotech ecosystem.
Based in Kendall Square, Cambridge, Pharma²⁸ connects U.S. biotech innovation with international clinical, regulatory, data and patient-access opportunities. Our first strategic market is Brazil, with a broader vision to support rare disease innovation across additional international markets over time.
The partners we work with.
Biotech companies
Advancing therapies for rare and ultra-rare diseases with international potential.
Physicians and research centers
Clinicians, physician-scientists and centers of excellence with disease-area expertise.
Healthcare institutions
Academic hospitals and specialty institutions ready to host rigorous programs.
Strategic stakeholders
Investors and partners aligned with responsible rare disease development.
Bringing Small Molecules to Life
A strategic brief on translating rare disease innovation across the Boston–Brazil corridor.
Let's connect.
If you are exploring international opportunities for a rare disease therapy, clinical program, data initiative or strategic partnership, we would welcome the opportunity to connect.